Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
Gwen Nichols, MDAcute Myeloid Leukemia | December 12, 2023
The goal of PedAL is to establish a data-driven developmental therapeutics program.
View More
Katie KoskoChronic Myeloid Leukemia | December 13, 2023
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
Katie KoskoMeeting News | December 11, 2023
Investigators reviewed cladribine in combination with low dose cytarabine (LDAC) and venetoclax.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Guido Marcucci, MDChronic Myeloid Leukemia | November 29, 2023
Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 2, 2023
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Advertisement
Cecilia BrownChronic Myeloid Leukemia | October 11, 2023
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Cecilia BrownChronic Myeloid Leukemia | February 8, 2024
The FDA also announced it approved a new capsule dosage form of bosutinib.
Jorge Cortes, MDVideo Insights | September 14, 2023
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Myeloid Leukemia | August 3, 2023
Researchers reviewed data from 107 patients with CML who developed a T315I mutation in BCR-ABL1.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Blood Cancers Today Staff WritersChronic Myeloid Leukemia | September 5, 2023
In this poor-risk population of patients, 73% responded to the triplet.
Cecilia BrownChronic Myeloid Leukemia | April 25, 2023
A study suggests a rationale for targeting PRMT5 in patients with relapsed or refractory MCL who have high mutation burdens.
Cecilia BrownChronic Myeloid Leukemia | November 30, 2023
The story of The Max Foundation begins with its namesake, Maximiliano “Max” M. Rivarola.
Simona Soverini, PhDVideo Insights | January 10, 2023
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Leah SherwoodMeeting News | December 10, 2022
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
Leah LawrenceChronic Myeloid Leukemia | February 14, 2023
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
Leah LawrenceChronic Myeloid Leukemia | December 9, 2022
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
Leah SherwoodChronic Myeloid Leukemia | February 6, 2023
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
Cecilia BrownChronic Myeloid Leukemia | November 14, 2022
With a growing number of treatment options, clinicians need guidance on the best third-line options for patients with CML.
Advertisement
Advertisement
Editorial Board